BMI View: The Netherlands has a well-developed healthcare system due to generous public expenditure
over the years. Despite newly introduced cost-cutting measures, government spending on healthcare will
continue to increase in local currency terms, especially as the wider eurozone recovers. However, the
country’s aging population will put pressure on government finances over the longer-term, inevitably
leading to further price caps on medicines.
Headline Expenditure Projections
? Pharmaceuticals: EUR5.92bn (USD7.93bn) in 2014 to EUR5.80bn (USD6.38bn) in 2015; -2.0% in
local currency terms and -19.6% in US dollar terms. Forecast in line with last quarter.
• Healthcare: EUR73.28bn (USD98.19bn) in 2014 to EUR74.29bn (USD81.72bn) in 2015; +1.4% in local
currency terms and -16.8% in US dollar terms. Forecast in line with last quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Netherlands 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2011-2019) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019) 17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019) 25
OTC Medicine Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Netherlands 2013-2019) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2013-2019) 31
Industry Risk Reward Index 32
Western Europe Risk/Reward Index 32
Netherlands Risk/Reward Index 38
Rewards 38
Risks 38
Regulatory Review 40
Regulatory Developments 42
Intellectual Property Regime 43
Pricing Regime 43
Reimbursement Regime 45
Market Overview 47
Healthcare Sector 48
Table: Healthcare Resources (Netherlands 2009-2014) 50
Table: Healthcare Personnel (Netherlands 2009-2014) 50
Table: Healthcare Activity (Netherlands 2009-2014) 51
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006 53
Table: Biosimilars Approved In The EU 56
Research & Development 57
Clinical Trials 59
Epidemiology 61
Competitive Landscape 63
Research-Based Industry 63
Table: Pharmaceutical Production, 1995-2010 (EUR '000s) 63
Table: Multinational Market Activity 65
Pharmaceutical Distribution 66
Pharmaceutical Retail Sector 66
Company Profile 69
DSM 69
GlaxoSmithKline 72
Merck & Co 74
Novartis 76
Pfizer 78
Pharming Group 80
Qiagen 83
Sanofi 86
Demographic Forecast 88
Demographic Outlook 88
Table: Population Headline Indicators (Netherlands 1990-2025) 89
Table: Key Population Ratios (Netherlands 1990-2025) 89
Table: Urban/Rural Population & Life Expectancy (Netherlands 1990-2025) 90
Table: Population By Age Group (Netherlands 1990-2025) 90
Table: Population By Age Group % (Netherlands 1990-2025) 91
Glossary 93
Methodology 95
Pharmaceutical Expenditure Forecast Model 95
Healthcare Expenditure Forecast Model 95
Notes On Methodology 96
Risk/Reward Index Methodology 97
Index Overview 98
Table: Pharmaceutical Risk/Reward Index Indicators 98
Indicator Weightings 99

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Netherlands 2013-2019)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2011-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019)
Table: Pharmaceutical Trade Data And Forecasts (Netherlands 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2013-2019)
Table: Healthcare Resources (Netherlands 2009-2014)
Table: Healthcare Personnel (Netherlands 2009-2014)
Table: Healthcare Activity (Netherlands 2009-2014)
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006
Table: Biosimilars Approved In The EU
Table: Pharmaceutical Production, 1995-2010 (EUR '000s)
Table: Multinational Market Activity
Table: Population Headline Indicators (Netherlands 1990-2025)
Table: Key Population Ratios (Netherlands 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Netherlands 1990-2025)
Table: Population By Age Group (Netherlands 1990-2025)
Table: Population By Age Group % (Netherlands 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators